Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements
TipRanksFeb 25 00:55 ET · Ratings
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
Yahoo FinanceFeb 15 07:21 ET
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
Yahoo FinanceFeb 15 07:14 ET
Strong Week for Enanta Pharmaceuticals (NASDAQ:ENTA) Shareholders Doesn't Alleviate Pain of Three-year Loss
Simply Wall StFeb 14 06:40 ET
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsFeb 13 01:31 ET · Ratings
Enanta Pharmaceuticals (ENTA) Receives a Buy From Evercore ISI
TipRanksFeb 13 00:44 ET · Ratings

Comments

Jaguar8

Feb 10 15:01

NEWS ER

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
Monday, 10th February at 4:01 pm
• On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025
• Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421
• On Track to Announce STAT6 Development Candidate in 2H 2025
• Operatio...

2

ApexTradeZ

Jan 5 17:20

Add to the WL 🫵🏻🥇💯

$Enanta Pharmaceuticals (ENTA.US)$
do you put much effort in the market to be early? I spend 10-16 hrs a day own (3) businesses and have a wife / (4) sons and a life but one is what they eat and i eat success and i win all the time…. find follow join and win connect to my efforts and win with me …..

thoughtful Narwhal_3

Dec 9, 2024 05:49

$Enanta Pharmaceuticals (ENTA.US)$ topline data looks good

Jaguar8

Dec 9, 2024 05:32

NEWS

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified ...

1

This_Guy

Dec 9, 2024 05:32

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral loa...

ENTA Enanta Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks